Inositol Hexaphosphate and Inositol Inhibit Colorectal Cancer Metastasis to the Liver in BALB/c Mice

• Published in: Nutrients 2016-05, Vol.8 (5), p.286-286
• Main Authors: Fu, Min, Song, Yang, Wen, Zhaoxia, Lu, Xingyi, Cui, Lianhua
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adenocarcinoma - prevention & control; Adenocarcinoma - secondary; angiogenesis; Animals; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Disease; ECM; Female; inositol; Inositol - administration & dosage; Inositol - therapeutic use; inositol hexaphosphate; Liver; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Medical prognosis; Metastasis; Mice; Mice, Inbred BALB C; Neoplasm Metastasis - prevention & control; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - pathology; Neoplasms, Experimental - secondary; Phytic Acid - administration & dosage; Phytic Acid - therapeutic use; Polyclonal antibodies; Random Allocation; Vascular endothelial growth factor
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu8050286

Inositol hexaphosphate (IP6) and inositol (Ins), naturally occurring carbohydrates present in most mammals and plants, inhibit the growth of numerous cancers both in vitro and in vivo. In this study, we first examined the anti-metastatic effects of IP6 and Ins using a liver metastasis model of colorectal cancer (CRC) in BALB/c mice. CT-26 cells were injected into the splenic capsule of 48 BALB/c mice. The mice were then randomly divided into four groups: IP6, Ins, IP6 + Ins and normal saline control (n = 12 per group). IP6 and/or Ins (80 mg/kg each, 0.2 mL/day) were injected into the gastrointestinal tracts of the mice on the second day after surgery. All mice were sacrificed after 20 days, and the tumor inhibition rates were determined. The results demonstrated that the tumor weights of liver metastases and the tumor inhibition rates were reduced in the experimental groups compared to the control group and that treatment with the combination of IP6 and Ins resulted in greater inhibition of tumor growth than treatment with either compound alone. These findings suggest that IP6 and Ins prevent the development and metastatic progression of colorectal cancer to the liver in mice by altering expression of the extracellular matrix proteins collagen IV, fibronectin and laminin; the adhesion factor receptor integrin-β1; the proteolytic enzyme matrix metalloproteinase 9; and the angiogenic factors vascular endothelial growth factor, basic fibroblast growth factor, and transforming growth factor beta in the tumor metastasis microenvironment. In conclusion, IP6 and Ins inhibited the development and metastatic progression of colorectal cancer to the liver in BALB/c mice, and the effect of their combined application was significantly greater than the effect of either compound alone. This evidence supports further testing of the combined application of IP6 and Ins for the prevention of colorectal cancer metastasis to the liver in clinical studies.